End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
45.61 CNY | +2.96% | +9.43% | +0.84% |
Apr. 26 | Hengrui Pharma Gets Nod to Trial Insulin Aspart Injection; Shares Up 3% | MT |
Apr. 17 | Jiangsu Hengrui Medicine Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- With an expected P/E ratio at 53.27 and 44.36 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- Revenue estimates are regularly revised downwards for the current and coming years.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+0.84% | 40.02B | B | ||
+25.83% | 661B | C+ | ||
+27.00% | 566B | B | ||
-6.76% | 352B | C+ | ||
+20.34% | 332B | B- | ||
+3.00% | 283B | C+ | ||
+13.09% | 231B | B+ | ||
+5.46% | 200B | B- | ||
-9.61% | 195B | A+ | ||
-6.26% | 145B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 600276 Stock
- Ratings Jiangsu Hengrui Medicine Co., Ltd.